摘要
目的分析局部晚期宫颈癌新辅助化疗的临床疗效和卫生经济学指标,评价新辅助化疗的临床应用价值及可推广性。方法对2013年6月至2015年6月在首都医科大学附属北京妇产医院初次治疗的113例局部晚期宫颈癌患者进行回顾分析,根据手术前有无新辅助化疗分为新辅助化疗组(NACT组)和直接手术组,比较2组患者术中出血量、手术时间、术后复发、术后辅助治疗及治疗费用。结果随访发现2组患者复发率差异无统计学意义,新辅助化疗在宫颈癌治疗方面,可以减少术中出血、缩短手术时间、减少淋巴转移及脉管癌栓,部分避免了辅助放化疗、减少了术后治疗费用,但治疗总费用高于直接手术组,差异有统计学意义。结论虽然直接手术组有较好的卫生经济效益,但新辅助化疗临床疗效好,为部分患者创造了手术条件,值得推广使用。
Objective To analyze the clinical effects and health economic indicators of neoadjuvant chemotherapy for local advanced cervical cancer, and to evaluate the clinical significance and the potential replication of neoadjuvant chemotherapy. Methods One hundred and thirteen cases of cervical cancer patients in the Beijing Obstetrics and Gynecology Hospital of Capital Medical University from June 2013 to June 2015 were analyzed. Patients were divided into the NACT group and the direct operation group. Bleeding volume, operation time, postoperative recurrence, postoperative treatment and the treatment costs were compared between the two groups. Results Neoadjuvant chemotherapy in the treatment of cervical cancer, could reduce intraoperative bleeding, shorten the operation time, reduce lymph node metastasis and vascular tumor thrombus, partially avoid the adjuvant treatment after operation, reduce the cost of treatment, but the total cost of treatment was higher than the direct operation group. Conclusion Although the direct operation group has better health and economic benefits than the NACT group, but the Neoadjuvant chemotherapy has good clinical effect, and it can be used in some patients to create the operation opportunity, therefore it is worth of promoting.
出处
《北京医学》
CAS
2016年第11期1153-1155,共3页
Beijing Medical Journal
基金
北京市科技计划(D151100001915001
D131100005313009)
关键词
局部晚期宫颈癌
新辅助化疗
卫生经济学评价
locally advanced cervical cancer
neoadjuvant chemotherapy
health economics evaluation
